RecruitingNot ApplicableNCT06989086
FearLess in NeuroOncology
FearLess in Neuro-Oncology
Sponsor
Virginia Commonwealth University
Enrollment
112 participants
Start Date
Jun 24, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers
Eligibility
Min Age: 18 Years
Inclusion Criteria11
- Patients:
- Self-report a diagnosis of a primary malignant brain tumor (grade II-IV)
- \>2 weeks post-cranial resection or biopsy
- Elevated Fear of Recurrence Distress Rating
- Primarily English speaking
- \>/= 18 years of age at the time of enrollment
- Caregivers:
- nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)
- Elevated Fear of Recurrence Distress Rating
- Primarily English speaking
- \>/= 18 years of age at the time of enrollment
Exclusion Criteria3
- Cognitive impairment that might prohibit active intervention engagement
- Inability to understand and provide informed consent
- Inability to attend virtual sessions due to unstable or no internet connection
Interventions
BEHAVIORALFearless in Neuro-Oncology
FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06989086
Related Trials
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT073265661 location
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT063441301 location
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
NCT071007304 locations
UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4
NCT074591011 location
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
NCT072680531 location